CAS 20987-24-0: (3beta,5beta,15beta,17xi)-3-hydroxy-19-oxo-14,15-epoxybufa-20,22-dienolide

Resibufagin is a cardiotonic steroid, which is derived from the secretions of the Asian toad, Bufo gargarizans. This compound is classified under bufadienolides, a group of naturally occurring steroids known for their distinctive structures and pronounced bioactivity. The primary mode of action of resibufagin involves the inhibition of the Na+/K+-ATPase enzyme, a crucial membrane-bound protein responsible for maintaining the electrochemical gradients of sodium and potassium ions across cell membranes. This inhibition disrupts ion homeostasis, leading to increased intracellular calcium levels, which enhances cardiac contractility. Resibufagin has been studied for its potential therapeutic applications, mainly in the field of cardiovascular medicine, owing to its positive inotropic effects. Additionally, there is interest in its potential anticancer properties, as emerging research suggests it may influence cancer cell proliferation and apoptosis through its impact on cellular signaling pathways. However, extensive clinical evaluations are necessary to establish its efficacy and safety profile. This compound continues to be an area of active investigation, offering valuable insights into cardiac physiology and potential novel therapeutic avenues.

Resibufagin shows strong cytotoxic activity against HeLa cell line.